Margaret Porter Scott

I joined Genentech because great science with great people is what I want do. I have spent my career seeking the best ways to “reduce to practice” the key aspects of highly complex disease biology so that new drug discovery programs can be initiated and progressed. This leads to a tight partnership with Disease Biology and I count myself so fortunate to have a role in Biochemical and Cellular Pharmacology focusing on the portfolio of cancer targets in partnership with the world-class Oncology Biology team here at Genentech. The team in Biochemistry and Cellular Pharmacology brings to projects combined large and small molecule expertise to help drive drug discovery programs with disease relevant, high quality assays and lead finding efforts.

The Therapeutic Antibody in vitro group has the opportunity of continuing the success of Genentech in discovering and developing novel biologics. We cover key aspects of antibody drug discovery and development including initial screening and characterization, in vitro mechanistic studies and bioanalytical support for PK and PD studies. In addition, the Antibody Drug Conjugate platform is an exciting opportunity to extend antibody-based therapies to a new set of indications.

With our uHTS and fragment screening platforms, we are engaged at the earliest stage of projects to help initiate new programs. Our role is to find and validate chemical matter to both initiate new chemistry efforts and to deliver tools to help better understand target biology. The team helps drive discovery programs by providing appropriate panels of enzyme and cell based assays to progress the potency of molecules as well as understand their mechanism of action. Degrees include a BA in Biochemistry from Oberlin College, and a PhD in Molecular and Cellular Biology from SUNY Stony Brook.